|
1
|
Gocek E and Marcinkowska E:
Differentiation therapy of acute myeloid leukemia. Cancers (Basel).
3:2402–2420. 2011. View Article : Google Scholar
|
|
2
|
Hughes PJ, Marcinkowska E, Gocek E,
Studzinski GP and Brown G: Vitamin D3-driven signals for myeloid
cell differentiation – implications for differentiation therapy.
Leuk Res. 34:553–565. 2010. View Article : Google Scholar :
|
|
3
|
Marchwicka A, Cebrat M, Sampath P,
Snieżewski L and Marcinkowska E: Perspectives of differentiation
therapies of acute myeloid leukemia: The search for the molecular
basis of patients' variable responses to 1,25-dihydroxyvitamin D
and vitamin D analogs. Front Oncol. 4:1252014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trump DL, Deeb KK and Johnson CS: Vitamin
D: Considerations in the continued development as an agent for
cancer prevention and therapy. Cancer J. 16:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gocek E, Kiełbiński M, Baurska H, Haus O,
Kutner A and Marcinkowska E: Different susceptibilities to
1,25-dihydroxyvitamin D3-induced differentiation of AML cells
carrying various mutations. Leuk Res. 34:649–657. 2010. View Article : Google Scholar
|
|
6
|
Gocek E, Marchwicka A, Baurska H, Chrobak
A and Marcinkowska E: Opposite regulation of vitamin D receptor by
ATRA in AML cells susceptible and resistant to vitamin D-induced
differentiation. J Steroid Biochem Mol Biol. 132:220–226. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee HJ, Muindi JR, Tan W, Hu Q, Wang D,
Liu S, Wilding GE, Ford LA, Sait SN, Block AW, et al: Low 25(OH)
vitamin D3 levels are associated with adverse outcome in newly
diagnosed, intensively treated adult acute myeloid leukemia.
Cancer. 120:521–529. 2014. View Article : Google Scholar :
|
|
8
|
Donovan PJ, Sundac L, Pretorius CJ,
d'Emden MC and McLeod DS: Calcitriol-mediated hypercalcemia: Causes
and course in 101 patients. J Clin Endocrinol Metab. 98:4023–4029.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bae JY, Kim JW and Kim I: Low-dose
1,25-dihydroxyvitamin D(3) combined with arsenic trioxide
synergistically inhibits proliferation of acute myeloid leukemia
cells by promoting apoptosis. Oncol Rep. 30:485–491.
2013.PubMed/NCBI
|
|
10
|
Clark CS, Konyer JE and Meckling KA:
1alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce
monocytic differentiation of NB4 acute promyelocytic leukemia cells
by modulating cell cycle progression. Exp Cell Res. 294:301–311.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim DS, Kim SH, Song JH, Chang YT, Hwang
SY and Kim TS: Enhancing effects of ceramide derivatives on
1,25-dihydroxyvitamin D(3)-induced differentiation of human HL-60
leukemia cells. Life Sci. 81:1638–1644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim SH, Yoo JC and Kim TS: Nargenicin
enhances 1,25-dihydroxyvitamin D(3)- and all-trans retinoic
acid-induced leukemia cell differentiation via PKCbetaI/MAPK
pathways. Biochem Pharmacol. 77:1694–1701. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Q, Harrison JS, Uskokovic M, Kutner A
and Studzinski GP: Translational study of vitamin D differentiation
therapy of myeloid leukemia: Effects of the combination with a p38
MAPK inhibitor and an antioxidant. Leukemia. 19:1812–1817. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Q, Salman H, Danilenko M and
Studzinski GP: Cooperation between antioxidants and
1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell
differentiation through the JNK/AP-1/Egr-1 pathway. J Cell Physiol.
204:964–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang J, Ikezoe T, Nishioka C, Ni L,
Koeffler HP and Yokoyama A: Inhibition of mTORC1 by RAD001
(everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3)
to induce growth arrest and differentiation of AML cells in vitro
and in vivo. Exp Hematol. 38:666–676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Irwin ME, Rivera-Del Valle N and Chandra
J: Redox control of leukemia: From molecular mechanisms to
therapeutic opportunities. Antioxid Redox Signal. 18:1349–1383.
2013. View Article : Google Scholar :
|
|
17
|
Hole PS, Darley RL and Tonks A: Do
reactive oxygen species play a role in myeloid leukemias? Blood.
117:5816–5826. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto T, Sakaguchi N, Hachiya M,
Nakayama F, Yamakawa M and Akashi M: Role of catalase in monocytic
differentiation of U937 cells by TPA: Hydrogen peroxide as a second
messenger. Leukemia. 23:761–769. 2009. View Article : Google Scholar
|
|
19
|
Bondza-Kibangou P, Millot C, El Khoury V
and Millot JM: Antioxidants and doxorubicin supplementation to
modulate CD14 expression and oxidative stress induced by vitamin D3
and seocalcitol in HL60 cells. Oncol Rep. 18:1513–1519.
2007.PubMed/NCBI
|
|
20
|
Stixová L, Procházková J, Soucek K,
Hofmanová J and Kozubík A: 5-Lipoxygenase inhibitors potentiate
1alpha,25-dihydroxyvitamin D3-induced monocytic differentiation by
activating p38 MAPK pathway. Mol Cell Biochem. 330:229–238. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Callens C, Coulon S, Naudin J,
Radford-Weiss I, Boissel N, Raffoux E, Wang PH, Agarwal S, Tamouza
H, Paubelle E, et al: Targeting iron homeostasis induces cellular
differentiation and synergizes with differentiating agents in acute
myeloid leukemia. J Exp Med. 207:731–750. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia
L, Liu W, Huang X, Jiang T, Wu MX, et al: Adenanthin targets
peroxiredoxin I and II to induce differentiation of leukemic cells.
Nat Chem Biol. 8:486–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu CX, Zhou HC, Yin QQ, Wu YL and Chen
GQ: Targeting peroxiredoxins against leukemia. Exp Cell Res.
319:170–176. 2013. View Article : Google Scholar
|
|
24
|
Ishii T, Warabi E and Yanagawa T: Novel
roles of peroxiredoxins in inflammation, cancer and innate
immunity. J Clin Biochem Nutr. 50:91–105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ray PD, Huang BW and Tsuji Y: Reactive
oxygen species (ROS) homeostasis and redox regulation in cellular
signaling. Cell Signal. 24:981–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Owusu-Ansah E and Banerjee U: Reactive
oxygen species prime Drosophila haematopoietic progenitors for
differentiation. Nature. 461:537–541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding Q, Jin T, Wang Z and Chen Y: Catalase
potentiates retinoic acid-induced THP-1 monocyte differentiation
into macrophage through inhibition of peroxisome
proliferator-activated receptor gamma. J Leukoc Biol. 81:1568–1576.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Poole LB, Hall A and Nelson KJ: Overview
of peroxiredoxins in oxidant defense and redox regulation. Curr
Protoc Toxicol. Chapter 7: Unit7.9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang B, Wang Y and Su Y: Peroxiredoxins,
a novel target in cancer radiotherapy. Cancer Lett. 286:154–160.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsukada J, Yoshida Y, Kominato Y and Auron
PE: The CCAAT/enhancer (C/EBP) family of basic-leucine zipper
(bZIP) transcription factors is a multifaceted highly-regulated
system for gene regulation. Cytokine. 54:6–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huber R, Pietsch D, Panterodt T and Brand
K: Regulation of C/EBPβ and resulting functions in cells of the
monocytic lineage. Cell Signal. 24:1287–1296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji Y and Studzinski GP: Retinoblastoma
protein and CCAAT/enhancer-binding protein beta are required for
1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60
cells. Cancer Res. 64:370–377. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marcinkowska E, Garay E, Gocek E, Chrobak
A, Wang X and Studzinski GP: Regulation of C/EBPbeta isoforms by
MAPK pathways in HL60 cells induced to differentiate by
1,25-dihydroxyvitamin D3. Exp Cell Res. 312:2054–2065. 2006.
View Article : Google Scholar : PubMed/NCBI
|
